Few studies have investigated the psychosocial impact of APOE ε4/ε4 genotype disclosure, and none in ethnic minorities.
Objective
We used mixed methods to investigate immediate responses to APOE ε4/ε4 genotype disclosure among Latino residents of northern Manhattan who participated in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) Study.
Methods
Eleven ε4 homozygotes received their genotype and a 55% risk estimate for developing Alzheimer's disease (AD) by age 85 from bilingual genetic counselors. Session recordings were transcribed and qualitative content analysis performed. One week after disclosure, distress levels were assessed through the intrusion subscale of the Impact of Event Scale-Revised (IES-R) and five items from the Impact of Genetic Testing in AD scale (IGT-AD) for 7/11 homozygotes, compared with participants with 0 (n = 61) or 1 (n = 47) ε4 alleles who also learned their APOE genotypes.
Results
Nine homozygotes were women; seven had an AD family history; age averaged 51 years. Participants with an AD family history or memory worries felt their concerns were validated; others were often surprised. Only one participant showed signs of elevated psychological distress. Responses on the IES-R intrusion subscale and IGT-AD items differed significantly from those of IDEAL participants who learned they had 0 or 1 ε4 alleles, but distress levels were low.
Conclusions
Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress.
BelloyMENapolioniVGreiciusMD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron2019; 101: 820–838.
2.
FarrerLACupplesLAHainesJL, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J Am Med Assoc1997; 278: 1349–1356.
3.
GeninEHannequinDWallonD, et al.APOE And Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry2011; 16: 903–907.
4.
QianJWoltersFJBeiserA, et al.APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med2017; 14: e1002254.
5.
ForteaJPeguerolesJAlcoleaD, et al.APOE4 Homozygozity represents a distinct genetic form of Alzheimer’s disease. Nat Med2024; 30: 1284–1291.
6.
ReimanEMGhisaysVLangbaumJB. The risk of Alzheimer disease in APOE4 homozygotes. JAMA Neurol2025; 82: 879–880.
7.
GoldmanJSHahnSECataniaJW, et al.Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med2011; 13: 597–605.
8.
FeldmanSJBlascoDMonesM, et al.Interest in and experience with genetic testing for late-onset medical conditions: results from the National Poll on Healthy Aging. J Prev Alzheimers Dis2024; 11: 1079–1086.
9.
WaterinkLMasselinkLAvan der LeeSJ, et al.Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study. Alzheimers Res Ther2024; 16: 1.
10.
FrankLAshfordJWBayleyPJ, et al.Genetic risk of Alzheimer’s disease: three wishes now that the genie is out of the bottle. J Alzheimers Dis2018; 66: 421–423.
11.
LangloisCMBradburyAWoodEM, et al.Alzheimer’s Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y)2019; 5: 705–716.
12.
MolinuevoJLCamiJCarneX, et al.Ethical challenges in preclinical Alzheimer’s disease observational studies and trials: results of the Barcelona summit. Alzheimers Dement2016; 12: 614–622.
13.
RitchieMSajjadiSAGrillJD. Apolipoprotein E genetic testing in a new age of Alzheimer disease clinical practice. Neurol Clin Pract2024; 14: e200230.
14.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
15.
CummingsJRabinoviciGDAtriA, et al.Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis2022; 9: 221–230.
16.
DanielEVKleimanMJGalvinJE. Exploring reasons for differential vulnerability and Alzheimer’s disease risk in racial and ethnic minorities. J Alzheimers Dis2023; 91: 495–506.
17.
QuirozYTSolisMArandaMP, et al.Addressing the disparities in dementia risk, early detection and care in Latino populations: highlights from the second Latinos & Alzheimer’s Symposium. Alzheimers Dement2022; 18: 1677–1686.
18.
KornblithEBahorikABoscardinWJ, et al.Association of race and ethnicity with incidence of dementia among older adults. J Am Med Assoc2022; 327: 1488–1495.
19.
MarquezDXPerezAJohnsonJK, et al.Increasing engagement of Hispanics/Latinos in clinical trials on Alzheimer’s disease and related dementias. Alzheimers Dement (N Y)2022; 8: e12331.
20.
ArandaMPMarquezDXGallagher-ThompsonD, et al.A call to address structural barriers to Hispanic/Latino representation in clinical trials on Alzheimer’s disease and related dementias: a micro-meso-macro perspective. Alzheimers Dement (N Y)2023; 9: e12389.
21.
WetmoreJBRodriguezSDiaz CaroD, et al.Designing and implementing the IDEAL study: a randomized clinical trial of APOE genotype disclosure for late-onset Alzheimer’s disease in an urban Latino population. Alzheimers Dement (N Y)2024; 10: e70016.
22.
TangMXCrossPAndrewsH, et al.Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology2001; 56: 49–56.
23.
TangMXMaestreGTsaiWY, et al.Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York city. Am J Hum Genet1996; 58: 574–584.
24.
TangMXSternYMarderK, et al.The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. J Am Med Assoc1998; 279: 751–755.
25.
GreenRCRobertsJSCupplesLA, et al.Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med2009; 361: 245–254.
26.
BemelmansSATrompKBunnikEM, et al.Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review. Alzheimers Res Ther2016; 8: 46.
27.
AlberJPopescuDThompsonLI, et al.Safety and tolerability of APOE genotyping and disclosure in cognitively normal volunteers from the Butler Alzheimer’s Prevention Registry. J Geriatr Psychiatry Neurol2022; 35: 293–301.
28.
LargentEABhardwajTAberaM, et al.Disclosing genetic risk of Alzheimer’s disease to cognitively unimpaired older adults: findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). J Alzheimers Dis2021; 84: 1015–1028.
29.
LangbaumJBBradburyAREglestonBL, et al.Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1. Lancet Healthy Longev2025; 6: 100778.
30.
ChaoSRobertsJSMarteauTM, et al.Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord2008; 22: 94–97.
31.
TaylorDHCook-DeeganRMHirakiS, et al.Genetic testing for Alzheimer’s and long-term care insurance. Health Aff Millwood2010; 29: 102–108.
32.
LineweaverTTBondiMWGalaskoD, et al.Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry2014; 171: 201–208.
33.
RamirezAGAparicio-TingFEde MajorsSS, et al.Interest, awareness, and perceptions of genetic testing among hispanic family members of breast cancer survivors. Ethn Dis2006; 16: 398–403.
34.
ZallenDT. Well, good luck with that’: reactions to learning of increased genetic risk for Alzheimer disease. Genet Med2018; 20: 1462–1467.
35.
KroenkeKSpitzerRLWilliamsJB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med2001; 16: 606–613.
36.
LivingstonGHuntleyJLiuKY, et al.Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet2024; 404: 572–628.
LautenbachDMChristensenKDSparksJA, et al.Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet2013; 14: 491–513.
39.
LiebermanJAStuartMR. The BATHE method: incorporating counseling and psychotherapy into the everyday management of patients. Prim Care Companion J Clin Psychiatry1999; 1: 35–38.
40.
ChungWWChenCACupplesLA, et al.A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord2009; 23: 50–56.
41.
WeissDSMarmarCR. The impact of event scale-revised. In: WilsonJPKeaneTM (eds) Assessing psychological trauma and PTSD: a practitioner’s handbook. New York: Guilford Press, 1997, pp.399–411.
42.
CreamerMBellRFaillaS. Psychometric properties of the Impact of Event Scale - Revised. Behav Res Ther2003; 41: 1489–1496.
43.
RobertsJS. Assessing the psychological impact of genetic susceptibility testing. Hastings Cent Rep2019; 49: S38–S43.
44.
Dedoose Version 9.0.107, cloud application for managing, analyzing, and presenting qualitative and mixed method research data. (2023).
45.
O’ConnorCJoffeH. Intercoder reliability in qualitative research: debates and practical guidelines. Int J Qual Methods2020; 19: 1609406919899220.
46.
FreemanGHHaltonJH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika1951; 38: 141–149.
47.
MengACabánMTranE, et al.Anticipated responses to genetic testing for Alzheimer’s disease susceptibility among Latinos in Northern Manhattan. J Community Health2025; 50: 472–482.
48.
BeckJGGrantDMReadJP, et al.The impact of event scale-revised: psychometric properties in a sample of motor vehicle accident survivors. J Anxiety Disord2008; 22: 187–198.
49.
MorinaNEhringTPriebeS. Diagnostic utility of the impact of event scale-revised in two samples of survivors of war. PloS One2013; 8: e83916.
50.
BarralSYangZPhillipsN, et al.APOE And Alzheimer’s disease and related dementias risk among 12,221 Hispanics/Latinos. Alzheimers Dement2025; 21: e70138.
51.
BonnerCTrevenaLJGaissmaierW, et al.Current best practice for presenting probabilities in patient decision aids: fundamental principles. Med Decis Making2021; 41: 821–833.
52.
HardenKP. Genetic determinism, essentialism and reductionism: semantic clarity for contested science. Nat Rev Genet2023; 24: 197–204.
53.
EckertSLKatzenHRobertsJS, et al.Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer’s disease: the REVEAL study. Genet Med2006; 8: 746–751.
54.
TranECabanMMengA, et al.Beliefs about the causes of Alzheimer’s disease among Latinos in New York City. J Community Health2025; 50: 10–22.
